Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation-Reference-Cited by-同舟云学术

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

Published:2016-03-17 Issue:11 Volume:127 Page:1502-1508
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Mielcarek Marco¹²,Furlong Terry¹,O’Donnell Paul V.¹²,Storer Barry E.¹³,McCune Jeannine S.¹⁴,Storb Rainer¹²,Carpenter Paul A.¹⁵,Flowers Mary E. D.¹²,Appelbaum Frederick R.¹²,Martin Paul J.¹²

Affiliation:

1. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA; and

2. Department of Medicine,

3. Department of Biostatistics,

4. School of Pharmacy, and

5. Department of Pediatrics, University of Washington, Seattle, WA

Abstract

Key Points With conventional immunosuppression, the incidence of chronic GVHD is higher after transplantation of mobilized blood compared with marrow. Administration of cyclophosphamide after mobilized blood cell transplantation is associated with a low incidence of chronic GVHD.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/11/1502/1392362/1502.pdf

Reference22 articles.

1. Reduced mortality after allogeneic hematopoietic-cell transplantation.;Gooley;N Engl J Med,2010

2. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.;Luznik;Semin Oncol,2012

3. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.;Luznik;Blood,2010

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients;Toxicology and Applied Pharmacology;2024-10

2. Graft Versus Host Disease Prophylaxis in Matched Donor Stem Cell Transplantation: Post-transplantation Cyclophosphamide Combinations Versus Methotrexate/Tacrolimus;Transplantation Proceedings;2024-09

3. Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide;Bone Marrow Transplantation;2024-08-24

4. Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation;European Journal of Haematology;2024-08-18

5. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention;Blood Advances;2024-08-15